Cell & Gene Therapy Commercialization Benchmarking

Functional Trends in Commercializing Gene Therapies within the US

‍

Situation

‍

Our client was looking to better understand how late-stage, pre-commercial, or recently launched cell and gene therapy companies evolved key functions to prepare for commercialization.

‍

Objective

‍

The objective was to provide insights into functions like R&D, IT, manufacturing, finance, and HR—along with spending, funding, and workforce metrics.

‍

Our Work

‍

10EQS conducted qualitative interviews and a quant survey, to gather benchmarking metrics on resource allocation, budget & spending, automation, emerging technologies, governance, and strategy alignment at cell & gene therapy companies.

‍

Project Team

• Ex-KPMG Consultant with extensive health & life sciences commercial & growth strategy experience
• 10EQS Delivery Operations (=PMO) providing quality assurance, process management and expert recruitment
• 9 industry experts
• 50 survey respondents

‍

Industry experts (excerpt)

• Former Executive Director Finance – Global Biopharmaceutical Company (US)
• Vice President, IT – Biotechnology Company (US)
• Head of Talent & Learning – Cell Therapy Company (US)
• Global Marketing Director, Strategy & Innovation – Biopharmaceutical Company (US)
• Former Chief Legal Officer – Biotechnology Company (US)

‍

Results

‍

The findings highlighted opportunities to optimize processes and adapt strategies for successful commercialization. Amongst others, 10EQS found that most companies are allocating >50% of total revenues to R&D spending and <3% to spending on advanced technologies within the commercial function. Further, companies are leveraging contract manufacturing organizations, and academic institutions as external partners.